A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

NCT07316062 | Not Yet Recruiting

• 1 other identifier: D133FR00236
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Conditions

Non-Small-Cell Lung

Keywords

NSCLC, chart review

Outcome Measures

Primary Outcomes (3)

• Treatment Patterns

  Proportion of patients with different treatment regimens

  Up to 50 months

• Proportion of unresected patients in SI/II/III

  Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively

  Up to 50 months

• CRT rate in USIII

  Proportion of patients who have CRT regimen among unresected SIII patients enrolled

  Up to 50 months

Secondary Outcomes (3)

• Treatment Duration

  Up to 50 months

• Patterns of recurrence

  Up to 50 months

• Guideline adoption rate

  Up to 50 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.

You may qualify if:

• Stage I-III at initial NSCLC diagnosis
• Aged ≥18 years at first diagnosis of NSCLC
• Timeframe of NSCLC diagnosis:
• For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

You may not qualify if:

• NSCLC is not the primary cancer diagnosis
• Patients with a recent history of other tumor or concurrent other tumor
• Patients participating in interventional clinical trials at time of initial diagnosis
• Patients with positive pregnancy status at the time of diagnosis

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (1)

Research Site

Beijing, China

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479; information.center@astrazeneca.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2025
• First Posted: January 5, 2026
• Study Start: April 15, 2026
• Primary Completion (Estimated): April 30, 2029
• Study Completion (Estimated): April 30, 2029
• Last Updated: January 5, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Locations

CN (1)